OABI
OmniAb, Inc.
Biotechnology
Market Cap$167M
5Y Perf.-84.9%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
OABI vs REGN vs BEAM vs CRL
Revenue, margins, valuation, and 5-year total return — side by side.
REGN
Regeneron Pharmaceuticals, Inc.
Biotechnology
Market Cap$73.68B
5Y Perf.+17.2%
BEAM
Beam Therapeutics Inc.
Biotechnology
Market Cap$3.23B
5Y Perf.-63.8%
CRL
Charles River Laboratories International, Inc.
Medical - Diagnostics & Research
Market Cap$8.98B
5Y Perf.-55.9%
OABI vs REGN vs BEAM vs CRL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | OABI | REGN | BEAM | CRL |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $167M | $73.68B | $3.23B | $8.98B |
| Revenue (TTM) | $29M | $14.92B | $132M | $4.03B |
| Net Income (TTM) | $-54M | $4.42B | $-65M | $-185M |
| Gross Margin | 82.8% | 84.5% | -64.2% | 24.9% |
| Operating Margin | -173.0% | 24.3% | -281.0% | 11.8% |
| Forward P/E | — | 15.3x | — | 16.4x |
| Total Debt | $20M | $2.71B | $294M | $3.07B |
| Cash & Equiv. | $26M | $3.12B | $295M | $214M |
OABI vs REGN vs BEAM vs CRL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
OABI
REGN
BEAM
CRL
| Stock | Sep 21 | May 26 | Return |
|---|---|---|---|
| OmniAb, Inc. (OABI) | 100 | 15.1 | -84.9% |
| Regeneron Pharmaceu… (REGN) | 100 | 117.2 | +17.2% |
| Beam Therapeutics I… (BEAM) | 100 | 36.2 | -63.8% |
| Charles River Labor… (CRL) | 100 | 44.1 | -55.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OABI vs REGN vs BEAM vs CRL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: REGN leads in 5 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Beam Therapeutics Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
OABI
OmniAb, Inc.
The Specific-Use Pick
OABI plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
REGN
Regeneron Pharmaceuticals, Inc.
The Income Pick
REGN carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 0.81, yield 0.5%
- Lower volatility, beta 0.81, Low D/E 8.7%, current ratio 4.13x
- Beta 0.81, yield 0.5%, current ratio 4.13x
- Better valuation composite
Best for: income & stability and sleep-well-at-night
BEAM
Beam Therapeutics Inc.
The Growth Play
BEAM is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 120.0%, EPS growth 82.3%, 3Y rev CAGR 31.9%
- 120.0% revenue growth vs OABI's -29.3%
- +93.9% vs OABI's -3.9%
Best for: growth exposure
CRL
Charles River Laboratories International, Inc.
The Long-Run Compounder
CRL is the clearest fit if your priority is long-term compounding.
- 119.2% 10Y total return vs REGN's 90.0%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BEAM | 120.0% revenue growth vs OABI's -29.3% |
| Value | REGN | Better valuation composite |
| Quality / Margins | REGN | 29.6% margin vs OABI's -187.6% |
| Stability / Safety | REGN | Beta 0.81 vs BEAM's 2.14, lower leverage |
| Dividends | REGN | 0.5% yield; 1-year raise streak; the other 3 pay no meaningful dividend |
| Momentum (1Y) | BEAM | +93.9% vs OABI's -3.9% |
| Efficiency (ROA) | REGN | 11.1% ROA vs OABI's -18.1%, ROIC 8.9% vs -19.7% |
OABI vs REGN vs BEAM vs CRL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
Segment breakdown not available.
FY 2025
OABI vs REGN vs BEAM vs CRL — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLREGNLAGGINGBEAM
Who Leads Where
REGN leads in 2 of 6 categories
CRL leads 2 • OABI leads 0 • BEAM leads 0 • 1 tied
Explore the data ↓BEAMBeam Therapeutics Inc.
0leads
OABIOmniAb, Inc.
0leads
CRLCharles River Laborat…
2leads
REGNRegeneron Pharmaceuti…
2leads
6 Total Categories
CATEGORYLEADERvs CRLvs OABIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
REGN4/6
Valuation MetricsMultiples, price ratios, and targets
CRL4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
REGN7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
CRL3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
REGN leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
REGN is the larger business by revenue, generating $14.9B annually — 515.6x OABI's $29M. REGN is the more profitable business, keeping 29.6% of every revenue dollar as net income compared to OABI's -187.6%. On growth, OABI holds the edge at +2.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | OABIOmniAb, Inc. | REGNRegeneron Pharmac… | BEAMBeam Therapeutics… | CRLCharles River Lab… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $29M | $14.9B | $132M | $4.0B |
| EBITDAEarnings before interest/tax | -$33M | $4.2B | -$355M | $757M |
| Net IncomeAfter-tax profit | -$54M | $4.4B | -$65M | -$185M |
| Free Cash FlowCash after capex | -$26M | $4.2B | -$384M | $391M |
| Gross MarginGross profit ÷ Revenue | +82.8% | +84.5% | -64.2% | +24.9% |
| Operating MarginEBIT ÷ Revenue | -173.0% | +24.3% | -2.8% | +11.8% |
| Net MarginNet income ÷ Revenue | -187.6% | +29.6% | -49.2% | -4.6% |
| FCF MarginFCF ÷ Revenue | -89.9% | +27.9% | -2.9% | +9.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.5% | +19.0% | -100.0% | +1.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +64.7% | -7.2% | +26.6% | -160.0% |
REGN leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
CRL leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, CRL's 13.0x EV/EBITDA is more attractive than REGN's 17.8x.
| Metric | OABIOmniAb, Inc. | REGNRegeneron Pharmac… | BEAMBeam Therapeutics… | CRLCharles River Lab… |
|---|---|---|---|---|
| Market CapShares × price | $167M | $73.7B | $3.2B | $9.0B |
| Enterprise ValueMkt cap + debt − cash | $162M | $73.3B | $3.2B | $11.8B |
| Trailing P/EPrice ÷ TTM EPS | -2.58x | 17.09x | -38.85x | -62.52x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 15.35x | — | 16.42x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.70x | — | — |
| EV / EBITDAEnterprise value multiple | — | 17.78x | — | 12.98x |
| Price / SalesMarket cap ÷ Revenue | 8.96x | 5.14x | 23.14x | 2.24x |
| Price / BookPrice ÷ Book value/share | 0.63x | 2.46x | 2.51x | 2.81x |
| Price / FCFMarket cap ÷ FCF | — | 18.06x | — | 17.31x |
CRL leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
REGN leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
REGN delivers a 14.3% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-20 for OABI. OABI carries lower financial leverage with a 0.08x debt-to-equity ratio, signaling a more conservative balance sheet compared to CRL's 0.95x. On the Piotroski fundamental quality scale (0–9), REGN scores 5/9 vs OABI's 2/9, reflecting solid financial health.
| Metric | OABIOmniAb, Inc. | REGNRegeneron Pharmac… | BEAMBeam Therapeutics… | CRLCharles River Lab… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -20.3% | +14.3% | -5.9% | -5.7% |
| ROA (TTM)Return on assets | -18.1% | +11.1% | -4.6% | -2.5% |
| ROICReturn on invested capital | -19.7% | +8.9% | -31.1% | +6.3% |
| ROCEReturn on capital employed | -24.0% | +10.2% | -33.3% | +8.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.08x | 0.09x | 0.24x | 0.95x |
| Net DebtTotal debt minus cash | -$5M | -$412M | -$1M | $2.9B |
| Cash & Equiv.Liquid assets | $26M | $3.1B | $295M | $214M |
| Total DebtShort + long-term debt | $20M | $2.7B | $294M | $3.1B |
| Interest CoverageEBIT ÷ Interest expense | — | 108.44x | 1.08x | 6.38x |
REGN leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
CRL leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in REGN five years ago would be worth $14,365 today (with dividends reinvested), compared to $1,506 for OABI. Over the past 12 months, BEAM leads with a +93.9% total return vs OABI's -3.9%. The 3-year compound annual growth rate (CAGR) favors CRL at -1.4% vs OABI's -24.8% — a key indicator of consistent wealth creation.
| Metric | OABIOmniAb, Inc. | REGNRegeneron Pharmac… | BEAMBeam Therapeutics… | CRLCharles River Lab… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -21.8% | -8.5% | +16.0% | -10.1% |
| 1-Year ReturnPast 12 months | -3.9% | +27.1% | +93.9% | +32.8% |
| 3-Year ReturnCumulative with dividends | -57.4% | -5.1% | -5.6% | -4.2% |
| 5-Year ReturnCumulative with dividends | -84.9% | +43.6% | -55.6% | -46.9% |
| 10-Year ReturnCumulative with dividends | -84.9% | +90.0% | +67.8% | +119.2% |
| CAGR (3Y)Annualised 3-year return | -24.8% | -1.7% | -1.9% | -1.4% |
CRL leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — REGN and BEAM each lead in 1 of 2 comparable metrics.
Risk & Volatility
REGN is the less volatile stock with a 0.81 beta — it tends to amplify market swings less than BEAM's 2.14 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BEAM currently trades 86.4% from its 52-week high vs OABI's 63.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OABIOmniAb, Inc. | REGNRegeneron Pharmac… | BEAMBeam Therapeutics… | CRLCharles River Lab… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.51x | 0.81x | 2.14x | 1.52x |
| 52-Week HighHighest price in past year | $2.30 | $821.11 | $36.44 | $228.88 |
| 52-Week LowLowest price in past year | $1.22 | $476.49 | $15.35 | $131.30 |
| % of 52W HighCurrent price vs 52-week peak | +63.9% | +86.4% | +86.4% | +79.5% |
| RSI (14)Momentum oscillator 0–100 | 42.5 | 44.9 | 60.9 | 57.2 |
| Avg Volume (50D)Average daily shares traded | 428K | 631K | 2.0M | 806K |
Evenly matched — REGN and BEAM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: OABI as "Buy", REGN as "Buy", BEAM as "Buy", CRL as "Buy". Consensus price targets imply 172.1% upside for OABI (target: $4) vs 12.9% for CRL (target: $205). REGN is the only dividend payer here at 0.48% yield — a key consideration for income-focused portfolios.
| Metric | OABIOmniAb, Inc. | REGNRegeneron Pharmac… | BEAMBeam Therapeutics… | CRLCharles River Lab… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $4.00 | $865.68 | $40.83 | $205.43 |
| # AnalystsCovering analysts | 9 | 48 | 27 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | +0.5% | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | — | 1 |
| Dividend / ShareAnnual DPS | — | $3.41 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +5.4% | 0.0% | +4.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
REGN leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CRL leads in 2 (Valuation Metrics, Total Returns). 1 tied.
Best OverallRegeneron Pharmaceuticals, … (REGN)Leads 2 of 6 categories
Loading custom metrics...
OABI vs REGN vs BEAM vs CRL: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is OABI or REGN or BEAM or CRL a better buy right now?
For growth investors, Beam Therapeutics Inc.
(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -29. 3% for OmniAb, Inc. (OABI). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 1x trailing P/E (15. 3x forward), making it the more compelling value choice. Analysts rate OmniAb, Inc. (OABI) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — OABI or REGN or BEAM or CRL?
On forward P/E, Regeneron Pharmaceuticals, Inc.
is actually cheaper at 15. 3x.
03Which is the better long-term investment — OABI or REGN or BEAM or CRL?
Over the past 5 years, Regeneron Pharmaceuticals, Inc.
(REGN) delivered a total return of +43. 6%, compared to -84. 9% for OmniAb, Inc. (OABI). Over 10 years, the gap is even starker: CRL returned +119. 2% versus OABI's -84. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — OABI or REGN or BEAM or CRL?
By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc.
(REGN) is the lower-risk stock at 0. 81β versus Beam Therapeutics Inc. 's 2. 14β — meaning BEAM is approximately 166% more volatile than REGN relative to the S&P 500. On balance sheet safety, OmniAb, Inc. (OABI) carries a lower debt/equity ratio of 8% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — OABI or REGN or BEAM or CRL?
By revenue growth (latest reported year), Beam Therapeutics Inc.
(BEAM) is pulling ahead at 120. 0% versus -29. 3% for OmniAb, Inc. (OABI). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, BEAM leads at 31. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — OABI or REGN or BEAM or CRL?
Regeneron Pharmaceuticals, Inc.
(REGN) is the more profitable company, earning 31. 4% net margin versus -347. 0% for OmniAb, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus -383. 1% for OABI. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is OABI or REGN or BEAM or CRL more undervalued right now?
On forward earnings alone, Regeneron Pharmaceuticals, Inc.
(REGN) trades at 15. 3x forward P/E versus 16. 4x for Charles River Laboratories International, Inc. — 1. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OABI: 172. 1% to $4. 00.
08Which pays a better dividend — OABI or REGN or BEAM or CRL?
In this comparison, REGN (0.
5% yield) pays a dividend. OABI, BEAM, CRL do not pay a meaningful dividend and should not be held primarily for income.
09Is OABI or REGN or BEAM or CRL better for a retirement portfolio?
For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc.
(REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 81)). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (REGN: +90. 0%, BEAM: +67. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between OABI and REGN and BEAM and CRL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: OABI is a small-cap quality compounder stock; REGN is a mid-cap deep-value stock; BEAM is a small-cap high-growth stock; CRL is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(OABI: 247.3% · REGN: 19.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.